{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:37:28Z","timestamp":1779291448801,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clml.2018.11.007","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T22:26:18Z","timestamp":1542061578000},"page":"e93-e97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement\/Mutation is Highly Responsive to Rituximab\/Ibrutinib Combination Therapy"],"prefix":"10.1016","volume":"19","author":[{"given":"Shahram","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rushang D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarfraz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tori","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rola","family":"Altoos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven C.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel O.","family":"Persky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.11.007_bib1","series-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","first-page":"229","year":"2008"},{"key":"10.1016\/j.clml.2018.11.007_bib2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.11.007_bib3","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/leu.2012.72","article-title":"Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease","volume":"26","author":"Royo","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.11.007_bib4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.007_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/10428199609067588","article-title":"Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma","volume":"21","author":"Pittaluga","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.11.007_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<850::AID-CNCR22>3.0.CO;2-Z","article-title":"Mantle cell lymphoma in leukemic phase: characterization of its broad cytologic spectrum with emphasis on the importance of distinction from other chronic lymphoproliferative disorders","volume":"86","author":"Wong","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.11.007_bib7","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A\u00a0subset of t(11;14) lymphoma with mantle features displays mutated IgVH genes and includes patients with good prognosis, non-nodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.007_bib8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.880.880","article-title":"Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma","volume":"114","author":"Hoster","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.007_bib9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.007_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.007_bib11","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.11.007_bib12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients","volume":"144","author":"van't Veer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.11.007_bib13","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood.V86.8.2892.2892","article-title":"P53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32)","volume":"86","author":"Louie","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.007_bib14","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2011.055715","article-title":"The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index","volume":"97","author":"Slotta-Huspenina","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.007_bib15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"European Mantle Cell Lymphoma Network. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.007_bib16","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.007_bib17","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2018.11.007_bib18","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies","volume":"32","author":"Ponader","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.11.007_bib19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.007_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.007_bib21","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2018.11.007_bib22","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.007_bib23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/ng1321","article-title":"Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR","volume":"36","author":"Ng","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2018.11.007_bib24","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3324\/haematol.2016.160192","article-title":"Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma","volume":"102","author":"Jallades","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.007_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492835","article-title":"Frequent mutations in natural killer\/T cell lymphoma","volume":"49","author":"Zhang","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.clml.2018.11.007_bib26","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1101\/gad.14.14.1810","article-title":"BCoR, a novel corepressor involved in BCL-6 repression","volume":"14","author":"Huynh","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.clml.2018.11.007_bib27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.molmed.2014.03.001","article-title":"Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis","volume":"20","author":"Hatzi","year":"2014","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.clml.2018.11.007_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.anndiagpath.2014.03.006","article-title":"Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and\/or 13q14","volume":"18","author":"Chapman-Fredricks","year":"2014","journal-title":"Ann Diagn Pathol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:02Z","timestamp":1761870722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018311947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2152265018311947"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.11.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement\/Mutation is Highly Responsive to Rituximab\/Ibrutinib Combination Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}